Galapagos NV

GLPG

Equity

ISIN BE0003818359 / Valor 2130343

Euronext - Euronext Amsterdam (2026-03-31)

EUR 26.18+3.07%

Galapagos NV
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Galapagos NV is a Belgium-based clinical-stage biotechnology company that discovers and develops small-molecule medicines primarily for inflammatory and fibrotic diseases. Using internal discovery platforms for target identification and medicinal chemistry, the company advances candidates through preclinical and clinical development and combines an in-house pipeline with strategic partnerships to support later-stage development and commercialization; a notable collaboration with Gilead Sciences has played a central role in the development and commercial strategy for several of its assets. Galapagos is publicly listed (Euronext Brussels and Nasdaq) and focuses on disease-modifying oral therapies, maintaining research operations in Europe and the United States while managing a portfolio that has seen both clinical progress and program setbacks typical of the biotech sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

12.6%1Y

-25.9%3Y

-60.4%5Y

Performance

31.4%1Y

29.3%3Y

33.1%5Y

Volatility